This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD) complicated by neuropathic pain in China.
Patients diagnosed with NMOSD in accordance with the criteria of the International Panel for Neuromyelitis Optica Diagnosis (IPND).
Patients were complicated with neuropathic pain, with a DN4 score ≥ 4.
NRS score for pain ≥ 4 points, and neuropathic pain has persisted for more than 3 months.
Patients receiving biological therapy and/or prednisone at a stable dose, with no adjustment of the treatment plan within 30 days before enrollment.
Subjects participating in other clinical studies.
Subjects who have used investigational drugs for pain control within 30 days before enrollment.
Subjects with a concurrent diagnosis of peripheral neuropathy.
Subjects with concurrent active central nervous system diseases.